Docs Who Lift

Dr. Ken Custer, President of Lilly's Cardiometabolic Health, joins Dr. Spencer Nadolsky and Dr. Karl Nadolsky for the first big pharma executive interview in Docs Who Lift history. He breaks down the new retatrutide and eluralintide data out of EASD, why Lilly bet on a selective amylin agonist, what drug development actually costs, and where pricing and access are headed.

The new U.S. Dietary Guidelines just dropped, and the internet is freaking out over the updated food pyramid. In this episode, we break down what the guidelines actually say, who they’re really written for (hint: mostly policymakers, not everyday people), and why the pyramid graphic can be more confusing than helpful. We also dig into the biggest inconsistencies like the push for more protein and “natural fats,” the mixed messaging on saturated fat, and the messy “processed foods” debate without a clear definition. Bottom line: there’s some reasonable advice here, but a lot of the hype is performative, and the real impact depends on how these guidelines get translated into actual policy like school lunches and federal programs.

In this episode, Dr. Spencer and Dr. Karl break down some of the strangest and most misunderstood GLP-1 side effects, from slimmer’s paralysis and foot drop to bladder spasms and post-bariatric reactive hypoglycemia. They walk through real patient cases, why these issues happen, and what clinicians and patients can do to spot them early and manage them safely.

In this episode, Dr. Spencer and Dr. Karl talk with Dr. Karin Nordin, behavioral change specialist and founder of Body Brain Alliance, about why most advice on motivation, discipline, and habits gets it wrong. They break down the science of behavior change, exploring how identity, self-efficacy, and “future self thinking” can help people finally follow through on healthy routines that last.